Pregabalin vs placebo
Pregabalin may leads to higher adverse effect: weight gain compared with placebo (low certainty).
- RR 4.35 [2.34, 8.11]8 studies · 2488 participantsLow
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Pregabalin may leads to higher adverse effect: weight gain compared with placebo (low certainty).
Pregabalin probably leads to higher treatment withdrawal for any reason compared with placebo (moderate certainty).
Pregabalin probably leads to higher treatment withdrawal due to adverse effects compared with placebo (moderate certainty).
Pregabalin may leads to higher adverse effect: ataxia compared with placebo (low certainty).
Pregabalin may leads to higher adverse effect: dizziness compared with placebo (low certainty).
Pregabalin showed no clear difference in adverse effect: fatigue compared with placebo (low certainty).
It is very uncertain whether homeopathic medicinal products (non‐individualised treatment) changes adverse events compared with placebo or usual care (very low certainty).
It is very uncertain whether homeopathic medicinal products changes short‐term cure1 compared with placebo or usual care (very low certainty).
It is very uncertain whether homeopathic medicinal products changes long‐term cure1 compared with placebo or usual care (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Homeopathic medicinal products (individualised treatment) showed no clear difference in recurrence of ARTI compared with placebo or usual care (moderate certainty).
Homeopathic medicinal products (individualised treatment) showed no clear difference in days off work for parents compared with placebo or usual care (moderate certainty).
Homeopathic medicinal products (individualised treatment) showed no clear difference in need for antibiotics compared with placebo or usual care (low certainty).
Homeopathic medicinal products (individualised treatment) showed no clear difference in adverse events compared with placebo or usual care (moderate certainty).